Home > Rheumatology > EULAR 2019 > Axial Spondyloarthritis > Treat-to-target approach emerging in axial spondyloarthritis

Treat-to-target approach emerging in axial spondyloarthritis

Presented By
Dr Pedro Machado, University College London Hospitals, United Kingdom
Conference
EULAR 2019
Trial
TICOPA, TICORA, TICOSPA
Observational evidence suggests that a treat-to-target (T2T) approach might be beneficial in axial spondyloarthritis. However, data from a prospective randomised study showing the efficacy of a T2T strategy compared to routine care are currently lacking. Additionally, there is no consensus about what should be measured and its specific target. These were the take-home messages presented by Dr Pedro Machado (University College London Hospitals, United Kingdom) discussing the pros and cons of adopting a T2T strategy in the management of axial spondyloarthritis [1]. The availability of biologic therapies has improved the clinical outcomes of patients with axial spondyloarthritis, which has raised the question if there is a role for T2T. Dr Machado explained that the concept involves changing or escalating therapy according to a predefined target, under the assumption that this may lead to better outcome compared to routine care. T2T is not only well establish...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on